Each material 8-K filed by a company listed on a US stock exchange (NYSE, Nasdaq, Cboe), read and summarized: what happened, the key numbers, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). This page lists the last 45 days; every brief stays on its company's 8-K page (1654 companies, A–Z).
Viridian Therapeutics reported positive phase 1 results for VRDN-008, an extended half-life FcRn inhibitor given subcutaneously, in six healthy volunteers. The company plans to focus its FcRn clinical development on VRDN-008 and to start at least one pivotal trial in 2027, beginning with myasthenia gravis in mid-2027, pending regulatory feedback.
Six healthy volunteers; IgG reduction of 74% at peak and sustained through eight weeks after subcutaneous dosing
Extended half-life of 15 to 18 days, five to six times longer than first-generation Fc fragments
First pivotal trial planned to start in mid-2027 in myasthenia gravis, pending regulatory feedback
Company plans to focus FcRn development on VRDN-008 and may pursue VRDN-006 in the future
Cullinan Therapeutics furnished a press release and 8-K describing interim clinical data from a Phase 1b/2a trial of velinotamig in patients with refractory systemic lupus erythematosus. The trial is run by Genrix in China, and Cullinan holds the global (ex-Greater China) license, so the results bear on the company's lead clinical asset, though the data are early and based on a small number of patients.
As of the September 8, 2026 data cutoff, 12 patients had been treated across three multi-dose cohorts, with no dose-limiting toxicities and no ICANS reported
Cytokine release syndrome occurred in two patients, limited to Grade 1 or 2 events; no Grade 3 or higher CRS was observed
Eight of nine evaluable patients achieved a reduction of at least four points in SLEDAI-2K
Four of seven evaluable patients with proteinuria above 500 mg/24 hours at baseline achieved a complete renal response within 24 weeks
Faeth Therapeutics reported preliminary topline results from its Phase 2 PIK-201 trial of PIKTOR with paclitaxel in 42 treated patients with advanced endometrial cancer, using an October 30, 2026 efficacy data cut. The confirmed objective response rate was 33% (12 of 36 efficacy-evaluable patients) and preliminary median progression-free survival was 7.4 months, and the company said the data support advancing to a Phase 3 trial. The results are preliminary, the trial is single-arm, and 64% of patients had a grade 3 or higher treatment-related adverse event.
Confirmed ORR of 33% (12 of 36); unconfirmed ORR of 36% (13 of 36); 44% confirmed ORR (7 of 16) in patients with a PIK3CA mutation
Preliminary median PFS of 7.4 months (95% CI 5.3 to NR); 6-month PFS rate of 62%
64% of patients had a grade 3 or higher treatment-related adverse event; 2 patients (5%) discontinued due to treatment-related adverse events; no treatment-related deaths
Company webcast held November 9, 2026 at 8:00 a.m. ET
Braveheart Bio and Hengrui Pharma presented 52-week open-label extension data from a Phase 2 study of HRS/BHB-1893 in 42 patients with obstructive hypertrophic cardiomyopathy (oHCM) at the American Heart Association Scientific Sessions 2026. The company reported gains in exercise capacity, symptoms and LVOT gradient, and also presented diastolic function data in non-obstructive HCM. The filing contains no financial results, and the company will hold an investor event today to discuss the data and a planned fixed-dose oHCM study.
At Week 52, peak oxygen uptake rose a mean of 2.7 mL/kg/min and KCCQ-CSS rose a mean of 17.3 points from OLE baseline.
At Week 52, 79% (33/42) of patients achieved a Valsalva LVOT gradient below 30 mmHg.
Two patients had transient LVEF reductions below 50%, and no on-treatment severe or serious adverse events were reported.
Investor event and webcast scheduled for November 6, 2026, at 3:35 p.m. CT (4:35 p.m. ET).
Pulse Biosciences reported interim six-month results from its PRECISE-BTN study of the nPulse Vybrance system for symptomatic benign thyroid nodules, presented at the American Thyroid Association meeting. In the interim dataset of 43 patients, 86% achieved at least 50% nodule volume reduction at six months, and no serious adverse events were reported. The results are early, cover a subset of the study's enrolled patients, and do not include financial figures.
86% of the 43 evaluated patients achieved at least 50% nodule volume reduction at six months, the primary endpoint
Median volume reduction was 72% at six months, with most reduction evident by the one-month visit
ThyPRO-39 quality of life score improved 78% from baseline; 82% of patients with baseline neck pressure or fullness reported full resolution at six months
No serious adverse events were reported; the company expects to report full six-month and 12-month data for all patients
Home BancShares said it received about $80.7 million from the borrower's sale of part of the collateral securing a $92.1 million non-performing loan relationship in its Texas market, completing the first phase of resolving the credit. The payment lowers the company's non-performing loan and asset ratios and leaves about $11.4 million in carrying amount, with a second phase expected in the fourth quarter of 2026 that could recover part of an amount charged off in 2024.
Payment of about $80.7 million received; proceeds were about 95% of the appraised value of the collateral sold
Remaining carrying amount of about $11.4 million, still classified as nonaccrual pending the second phase
Based on September 30, 2026 balances, non-performing loans to total loans fall about 48 basis points and non-performing assets to total assets fall about 34 basis points
Second phase expected to complete in the fourth quarter of 2026, but the company gives no assurance the remaining balance will be repaid as expected
Northwest Bancshares furnished an investor presentation under Item 7.01 for its participation in the 2026 Hovde Financial Services Conference on November 5, 2026. The deck, dated November 4, 2026, reports third-quarter 2026 revenue of $184.9 million, which the company describes as a record quarter, and diluted EPS of $0.34 (adjusted EPS $0.35).
Conference participation: 2026 Hovde Financial Services Conference on Thursday, November 5, 2026; presentation dated November 4, 2026 (Exhibit 99.1)
3Q26 revenue of $184.9 million, up 9.9% year over year and 2.0% quarter over quarter; net interest income of $149.0 million, up 9.5% year over year
3Q26 diluted EPS of $0.34 and adjusted diluted EPS of $0.35; total loans of $13.3 billion and total deposits of $14.3 billion as of September 30, 2026
Cencora reorganized its operating model and will report three segments starting in fiscal 2027: Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other. The company also furnished unaudited revised segment results for fiscal 2026 and 2025 under the new structure, which show total revenue of $337.4 billion and total segment operating income of $4.8 billion for fiscal 2026, up from $321.3 billion and $4.2 billion in fiscal 2025.
Beginning in the first quarter of fiscal 2027, reporting segments are Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other
Fiscal 2026 total revenue was $337,397,299 thousand, compared with $321,332,819 thousand in fiscal 2025
Fiscal 2026 total segment operating income was $4,813,047 thousand, compared with $4,222,973 thousand in fiscal 2025
MWI Animal Health, Profarma and other PharmaLex components are in Other, a non-reportable category where the company is exploring strategic alternatives
FirstCash furnished an November 2026 investor presentation as Exhibit 99.1 to this 8-K and posted it on its website. The deck shows revenue up 18%, GAAP EPS up 25% and adjusted EPS up 19% versus the prior year, and it reiterates the pending Ramsdens acquisition and a 10% dividend increase for shareholders.
Trailing twelve-month figures as of September 30, 2026: revenue of $4.3 billion, GAAP net income of $406 million and adjusted EBITDA of $835 million
Fourth quarter dividend declared at $0.46 per share, a 10% increase over the prior quarterly dividend, annualizing to $1.84 per share
$176 million remains under the $350 million share repurchase program, with 1.6 million shares repurchased year to date at an average price of $201.04
Ramsdens acquisition has an estimated equity value of about $304 million and is targeted to close by the end of 2026, pending antitrust approval
Bread Financial reported September 2026 credit metrics, including a delinquency rate of 5.57%, down from 6.04% a year earlier. Average credit card and other loans rose 6.4% year over year for the month, to $18.74 billion. The release does not include revenue, earnings or guidance, and the filing gives no prior-year comparison for net principal loss rates.
Delinquency rate was 5.57% as of September 30, 2026, versus 6.04% as of September 30, 2025.
Net principal loss rate was 5.99% for September 2026 and 6.40% for the three months ended September 30, 2026.
Average credit card and other loans rose 6.4% year over year for September to $18.74 billion; end-of-period loans were $18.85 billion.
NETSTREIT furnished an updated third quarter 2026 investor presentation under Regulation FD, attached as Exhibit 99.1 and posted on its website. The deck includes unaudited Q3 2026 results showing higher revenue and net income than in Q3 2025, along with portfolio, liquidity and balance sheet data as of September 30, 2026.
Total revenues for the three months ended September 30, 2026 were $66.3 million, compared with $48.3 million a year earlier.
Net income attributable to common stockholders was $8.5 million, compared with $0.6 million in the prior-year quarter.
Diluted earnings per share were $0.08, compared with $0.01 a year earlier.
Total liquidity was $1.3 billion and unsettled forward equity was $312 million as of September 30, 2026.
At its 2026 Investor Meeting on October 19, 2026, Jefferies presented trailing 12-month results that management described as strong, including net revenues of $8.5 billion, net earnings above $935 million, and a return on tangible equity of 13.1%. Management said it expects investment banking and capital markets margins to keep expanding and that it expects to close the Hildene transaction in the first quarter of 2027.
Trailing 12-month net revenues of $8.5 billion, net earnings over $935 million, and return on tangible equity of 13.1%
Investment banking and capital markets segment revenue rose from $4.5 billion in 2023 to $7.8 billion, and pre-tax profit rose from $500 million to about $1.3 billion
Over $925 million returned to shareholders in the current year through buybacks and dividends
Management expects to close the Hildene transaction in the first quarter of 2027
Synchrony Financial filed monthly credit statistics for the thirteen months through September 30, 2026, as an unaudited exhibit to an 8-K. For September 2026, the net charge-off rate was 4.7%, down from 5.3% in September 2025, and the 30+ day delinquency rate was 4.3%, down from 4.4%. The company said it will keep publishing these figures monthly, with quarter-end months released alongside its earnings.
Net charge-off rate was 4.7% for September 2026, versus 5.3% for September 2025.
Adjusted net charge-off rate, a non-GAAP measure, was 4.6% for September 2026, versus 5.1% a year earlier.
30+ day delinquency rate was 4.3% at September 30, 2026, versus 4.4% at September 30, 2025.
Period-end loan receivables were $103.3 billion at September 30, 2026, versus $100.2 billion a year earlier.
Jefferies Financial Group posted an investor presentation on its website for its October 19, 2026 investor meeting, furnished as Exhibit 99.1 to a Form 8-K. The deck reports trailing-twelve-month results through the third quarter of 2026, including $8.5 billion in net revenues and $0.9 billion in net earnings to all shareholders, and it reviews its pending acquisition of Hildene/SILAC and a planned Japan Equities joint venture with SMBC.
Presentation posted October 19, 2026 for the company's October 19, 2026 Investor Meeting; filed as Exhibit 99.1
LTM Q3'26 net revenues of $8.5 billion, up 119% since 2019; net earnings to all shareholders of $0.9 billion, up 123% since 2019
Pending acquisition: Jefferies intends to acquire a 50% interest in Hildene Holding Company, which is acquiring SILAC, as disclosed in September 2025
Japan Equities joint venture with SMBC is scheduled to launch January 1, 2027
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Frequently asked questions
Which filings get a brief?
Form 8-K filings by companies listed on a US stock exchange (NYSE, Nasdaq, Cboe; not over-the-counter stocks) that report a material event: results (Item 2.02), deals (1.01, 2.01), executive changes (5.02), restructuring (2.05), impairments (2.06), delisting notices (3.01), restatements (4.02), cybersecurity incidents (1.05), bankruptcy (1.03) and Regulation FD or other events (7.01, 8.01). Routine filings such as vote results or exhibits only are skipped.
How is the impact score set?
The AI rates each filing from 1 (routine) to 5 (major, such as a merger, bankruptcy or restatement) based only on what the filing says. It is a reading aid for sorting the day's filings, not a prediction of how the stock will move.
How quickly do briefs appear?
On weekdays the SEC filing feed is checked every 5 minutes from 6 am to 5:45 pm Eastern, when nearly all 8-Ks come in, and every hour after that until 10 pm. Briefs of the 1,000 largest companies follow within minutes; the others usually within the hour, or later the same day when many filings arrive at once.
Which companies are covered?
Every company with shares listed on the NYSE, Nasdaq or Cboe that files 8-Ks, about 4,500 of them. Foreign companies that report on Form 6-K instead are not included. The S&P 1500 only filter above narrows the list to the large, mid and small caps of the S&P Composite 1500.
Are older briefs kept?
Yes. This page shows the last 45 days, but every brief ever published stays online: each has its own page, and each company has an 8-K page listing all of its briefs, newest first, linked from its stock page and from the A-Z list of companies.